Clinical Trial Update: A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema [Phase 3]

View source ↗

Summary

Pfizer is conducting a long-term Phase 3 study of Abrocitinib for moderate-to-severe atopic dermatitis in children aged 2 years and older; the trial is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Cibinqo (abrocitinib)

Snippet

Sponsor: Pfizer | Conditions: Atopic Dermatitis | Phase 3 | Status: RECRUITING